ArticlePsychiatry investigation2026
The Impact of 5-HTTLPR Polymorphism on Depression and Lymphocyte Changes in Colorectal Cancer Patients Undergoing FOLFOX Chemotherapy.
Article in Psychiatry investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
objectiveDepression could be related to immune function among cancer patients. The serotonin transporter gene has been reported for its associations with both depression and immune regulation. This study investigates the interaction between depression, immunity, and 5-HT transporter gene-linked polymorphism (5-HTTLPR) among colorectal cancer (CRC) patients undergoing chemotherapy.
methodsThis prospective longitudinal study collected information on depression and lymphocyte percentages at two time points: the first cycle and the final cycles of 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy. Clinical depression was assessed using the Hospital Anxiety and Depression Scale-depression subscale (HADS-D) score. Genotyping identified 5-HTTLPR alleles. The dependent variables were changes in the percentages of CD4+, CD8+, CD19+, and CD16/56+ lymphocytes between the two time points. Moderated regression analysis was used to find interactions.
resultsAmong 104 patients, no significant direct associations were observed between changes in lymphocyte percentages and HADS-D scores. However, with the interaction of 5-HTTLPR polymorphism, the moderated regression analysis revealed two significant associations between HADS-D scores and changes in the percentages of CD4+ and CD16/56+ lymphocytes. Specifically, the percentage of CD4+ cells decreased, and the percentage of CD16/56+ cells increased, in relation to the s allele as depression worsened. These findings were consistent in a sensitivity analysis.
conclusionChanges in the percentage of CD4+ cells and CD16/56+ cells under depression were moderated by 5-HTTLPR alleles among CRC patients undergoing FOLFOX chemotherapy, suggesting a gene-environment interaction. Further research on the role of 5-HTTLPR in the immune system under depression among CRC patients is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.